A Phase 3 interventional study of Losartan Potassium and Comparator: Placebo (Losartan) in Proteinuria, sponsored by Organon and Co. Completed. Open to participants aged 12 Months to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-23.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing losartan in Proteinuria — 1 open to participants now, 1 under way, none of them phase 3. Losartan · Proteinuria.
Among the 15 studies testing losartan in Proteinuria, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2007, is one of 5 in phase 3, and was the 8th registered.
329 studies on the registry are indexed under Proteinuria; 44 are open to participants now.
Browse Proteinuria studies →1 of the 15 studies testing losartan in Proteinuria is open now, in 1 country. Recruiting first, the newest first:
RESnTEC, Institute of Research · Sites in Pakistan
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 32 Proteinuria studies recruiting now, 12 (38%) set no upper age limit and 16 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.
This study: 12 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 306 is above the median of 54 across 240 interventional studies indexed under Proteinuria.
Median enrollment 164 across the 14 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Organon & Co. has 1 study filed under Proteinuria — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing losartan in Proteinuria, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.
The study included a 12-week double-blind treatment phase and a 36-month open-label extension phase. Participants who completed or discontinued the initial 12-week phase of the study and who opted to participate in the open label extension phase were randomized to either losartan or enalapril at a dose of the investigator's choosing for the duration of the extension. The open label extension was designed to continue until the 100th participant completed 3 years of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Normotensive participants received losartan. Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo).
Drug: Losartan Potassium · Other: Comparator: Placebo (Losartan)
Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
Other: Comparator: Placebo (Losartan) · Drug: Comparator: amlodipine besylate · Other: Comparator: Placebo (amlodipine besylate) · Other: Placebo (Losartan)
Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
Drug: Losartan Potassium
Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
Drug: Enalapril Maleate
Losartan Use During the Double-Blind Treatment Phase: Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg) or 100 mg/day (if the patient weighed ≥50 kg). Losartan Use During the Treatment Extension Phase: Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance.
Also known as: Cozaar®
Placebo (losartan suspension), administered orally, once daily for 12 weeks
Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
Also known as: NORVASC®
Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
Also known as: NORVASC®
Normotensive patients randomized to losartan placebo for 12 weeks.
Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
Also known as: Vasotec®, Renitec®
Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12
Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately twelve weeks of treatment. Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period.
Time frame: Baseline and Week 12
Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36
Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately three years of treatment. \*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase.
Time frame: Baseline and Month 36
Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36
The outcome measure of glomerular filtration rate was based on mL/min/1.73m\^2, as determined by the Schwartz formula: GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL) GFR values were compared to the baseline GFR measure. \[Note: For male participants, ages 13 to 17 years, 0.70 was used as the multiplier in place of 0.55\] Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase.
Time frame: Baseline and Month 36
Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12
Time frame: Baseline and Week 12
Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12
Time frame: Baseline and Week 12
As of March 2011, the study was completed. Phase III First Patient In: 21Jun07; Last Patient Last Visit (double-blind base study): 16Sep08; and (open-label extension): 31Mar11. The study included 52 centers (USA, Europe, Latin America, and Asia) and participants included children aged 6-17 (hypertensive) or 1-17 (normotensive) with proteinuria.
| Milestone | Losartan Double Blind Normortensive | Placebo Double Blind Normotensive | Losartan Double Blind Hypertensive | Amlodipine Double Blind Hypertensive | Losartan Open Label Extension | Enalapril Open Label Extension |
|---|---|---|---|---|---|---|
| Started | 122 | 124 | 30 | 30 | 0 | 0 |
| Completed | 116 | 118 | 29 | 25 | 0 | 0 |
| Not completed | 6 | 6 | 1 | 5 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Losartan Double Blind Normortensive | Placebo Double Blind Normotensive | Losartan Double Blind Hypertensive | Amlodipine Double Blind Hypertensive | Losartan Open Label Extension | Enalapril Open Label Extension |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 134 | 134 |
| Completed | 0 | 0 | 0 | 0 | 55 | 54 |
| Not completed | 0 | 0 | 0 | 0 | 79 | 80 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 11 | 8 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 6 | 11 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 9 | 8 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Termination of trial | 0 | 0 | 0 | 0 | 45 | 47 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 | 4 |
Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately twelve weeks of treatment. Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period.
| Percent Change in Pr/Cr | Losartan | Amlodipine/Placebo |
|---|---|---|
| Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12 | -35.80 (-43.11 to -27.55) | 1.37 (-10.27 to 14.51) |
| mm Hg | Losartan-Hypertensive Participants | Amlodipine-Hypertensive Participants |
|---|---|---|
| Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12 | -5.5 (-8.6 to -2.4) | -0.1 (-3.3 to 3.1) |
| mm Hg | Losartan-Hypertensive Participants | Amlodipine-Hypertensive Participants |
|---|---|---|
| Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12 | -3.8 (-7.0 to -0.7) | 0.8 (-2.5 to 4.1) |
Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\*, after approximately three years of treatment. \*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase.
| Percent Change in Pr/Cr | Losartan Open Label Extension | Enalapril Open Label Extension |
|---|---|---|
| Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36 | -30.01 ± 5.02 | -40.45 ± 2.10 |
The outcome measure of glomerular filtration rate was based on mL/min/1.73m\^2, as determined by the Schwartz formula: GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL) GFR values were compared to the baseline GFR measure. \[Note: For male participants, ages 13 to 17 years, 0.70 was used as the multiplier in place of 0.55\] Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase.
| Change in GFR mL/min1.73m^2 | Losartan Open Label Extension | Enalapril Open Label Extension |
|---|---|---|
| Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36 | 3.3 ± 66.3 | 7.0 ± 53.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Losartan: Double-Blind Base Study | — | 8/152 (5.3%) | 71/152 (46.7%) |
| Amlodipine/Placebo: Double-Blind Base Study | — | 5/154 (3.2%) | 66/154 (42.9%) |
| Losartan Open-Label Extension | — | 27/134 (20.1%) | 83/134 (61.9%) |
| Enalapril: Open-Label Extension | — | 25/134 (18.7%) | 78/134 (58.2%) |
| Event | Losartan: Double-Blind Base Study | Amlodipine/Placebo: Double-Blind Base Study | Losartan Open-Label Extension | Enalapril: Open-Label Extension |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/152 | 0/154 | 2/134 | 3/134 |
| PyelonephritisInfections and infestations | 0/152 | 0/154 | 3/134 | 0/134 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/152 | 0/154 | 1/134 | 3/134 |
| Renal failure acuteRenal and urinary disorders | 0/152 | 0/154 | 3/134 | 2/134 |
| LeukopeniaBlood and lymphatic system disorders | 0/152 | 0/154 | 2/134 | 0/134 |
| DiarrhoeaGastrointestinal disorders | 0/152 | 0/154 | 0/134 | 2/134 |
| Urinary tract infectionInfections and infestations | 0/152 | 2/154 | 2/134 | 1/134 |
| ConvulsionNervous system disorders | 0/152 | 0/154 | 1/134 | 2/134 |
| HaematuriaRenal and urinary disorders | 0/152 | 0/154 | 2/134 | 1/134 |
| Renal impairmentRenal and urinary disorders | 0/152 | 0/154 | 2/134 | 1/134 |
| Event | Losartan: Double-Blind Base Study | Amlodipine/Placebo: Double-Blind Base Study | Losartan Open-Label Extension | Enalapril: Open-Label Extension |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 24/152 | 19/154 | 31/134 | 20/134 |
| PharyngitisInfections and infestations | 6/152 | 6/154 | 21/134 | 20/134 |
| HeadacheNervous system disorders | 13/152 | 20/154 | 7/134 | 12/134 |
| VomitingGastrointestinal disorders | 6/152 | 4/154 | 16/134 | 4/134 |
| Upper respiratory tract infectionInfections and infestations | 7/152 | 9/154 | 15/134 | 9/134 |
| DiarrhoeaGastrointestinal disorders | 8/152 | 7/154 | 12/134 | 7/134 |
| AnaemiaBlood and lymphatic system disorders | 0/152 | 0/154 | 11/134 | 8/134 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/152 | 6/154 | 8/134 | 11/134 |
| Urinary tract infectionInfections and infestations | 2/152 | 3/154 | 10/134 | 10/134 |
| BronchitisInfections and infestations | 9/152 | 8/154 | 9/134 | 9/134 |
| Age, Continuous(years) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| Mean | 10.4 ± 4.7 | 9.7 ± 4.6 | 10.1 ± 4.7 |
| Age, Customized(participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| ≤6 Years of Age | 33 | 42 | 75 |
| 7-12 Years of Age | 57 | 57 | 114 |
| 13-17 Years of Age | 62 | 55 | 117 |
| Sex: Female, Male(Participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| Female | 66 | 64 | 130 |
| Male | 86 | 90 | 176 |
| Ethnicity (NIH/OMB)(Participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 79 | 82 | 161 |
| Not Hispanic or Latino | 73 | 72 | 145 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Hypertensive(Participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| Yes | 30 | 30 | 60 |
| No | 122 | 124 | 246 |
| Prior Angiotensin Converting Enzyme Inhibitor /Angiotensin II Type I Receptor Blocker (ACE-I/ARB)Use(Participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| Yes | 83 | 81 | 164 |
| No | 69 | 73 | 142 |
| Race(participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| Asian | 26 | 26 | 52 |
| Black | 5 | 5 | 10 |
| Multi-Racial | 36 | 34 | 70 |
| White | 77 | 85 | 162 |
| Other | 8 | 4 | 12 |
| Region(Participants) | Losartan | Amlodipine/Placebo | Total |
|---|---|---|---|
| United States | 15 | 10 | 25 |
| Outside of United States | 137 | 144 | 281 |
8 further baseline measures are reported on the registry.
No study locations are listed for this record.
Plan to share: No
Ran from Jun 2007 to primary completion in Sep 2008, 15 months.
Results were first posted in Oct 2009, 1 year 1 month after primary completion.
Of 20 phase 3 interventional studies under Proteinuria, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 78. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan